In brief

In brief

  • Accenture’s study with 130 oncologists from the US and Europe revealed that despite the promise of precision oncology, adoption is slow.
  • More than 80% of oncologists believe precision oncology is important, yet most don’t fulfill the critical elements for adoption in clinical practice.
  • Oncologists told us they need data, clinical decision support and evolved education to make precision oncology work.
  • Now is the time to take four essential steps to gain widespread adoption of precision oncology.

The days of one-size-fits-all therapies are being replaced by individualized treatments and disease interventions. In cancer, standard therapies are ineffective in an average of three-quarters of patients, one of the highest therapy failure rates for all diseases.1 Precision oncology describes a diverse set of strategies in cancer medicine tailored to the unique biology of a patient’s disease. Strategies range from the use of targeted therapies to the use of data from next-generation sequencing to select treatments independent of cancer-type. Precision oncology holds the promise of improved efficiency, better care and the reduction of ineffective treatments and costs. However, important work remains to prepare the oncological ecosystem to leverage the full potential of personalized medicine in oncology. To test the status quo, identify barriers to adoption and help unlock precision oncology’s full value, we surveyed 130 oncologists from the US and Europe as part of the Accenture Study on Precision Oncology in Practice.

The future of precision oncology hinges on adoption

Oncologists say they need:

1. Data

Real-world data sets are only as reliable as the quality of the underlying data. The more data, the more robust the decisions they support.

3. Evolved Precision Oncology Education

As fast-evolving treatment options and emerging technologies continue to multiply, oncologist need to master new skillsets.

View All


of respondents rank outcomes/longitudinal data as the most critical data source to share.


or less of oncologists today do not routinely participate in any molecular tumor boards or routinely use CDS tools.


of oncologists believe that clinical practice is changing rapidly and will require them to master new skillsets.

Steps to drive precision oncology adoption

It’s clear that precision oncology’s importance will grow significantly in the next few years, but to achieve the desired goals, a clear course must be plotted. Our research shows the oncology ecosystem requires four essential steps to capture the full benefits of precision medicine oncology:

Build the basics

Physicians need support through seamless exchange with peers and experts, and CDS tools using advanced analytics and RWE to interpret patient data.

Think beyond borders

We must expand the oncological data ecosystem across borders and drive a common approach to data collection, accreditation and standardization.

Reimagine medical education

We need digital technology and genomics education to interpret molecular foundations of each individual cancer in technology-enabled solutions.

Make healthcare professionals’ lives easier

Precision oncology adds complexity to everyday clinical practice. We need to align to clinical workflow, integrate technology and collaborate.

View All

1 Spear, B. B., Heath-Chiozzi, M. & Huff, J. Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201–204 (2001)

Dr. Boris Bogdan

Managing Director, Lead – Global Precision Oncology and PHC, Life Sciences

Dr. Mathias Ganter

Senior Manager – Life Sciences

Dr. Sandra Dietschy-Kuenzle

Senior Principal – Life Sciences


Biopharma’s golden opportunity
Navify Tumor Board: Improving cancer care

Subscription Center
Visit our Subscription and Preference Center Visit our Subscription and Preference Center